SNDX•benzinga•
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth
Summary
JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 21, 2025 by benzinga